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The myriad changes that occur during the malignant progression of cancer cells present chal-
lenges to both clinicians and basic scientists. Two new studies in Nature underscore the central 
role of genome instability in tumor biology (Edwards et al., 2008; Sakai et al., 2008). These reports 
describe secondary changes in the BRCA2 locus that restore the wild-type reading frame and 
contribute to the development of resistance to chemotherapeutic agents.Tumorigenesis involves numerous 
genetic alterations, some of which 
are selected for if they promote tumor 
growth, survival, metastasis, or resis-
tance to treatment (Merlo et al., 2006; 
Vogelstein and Kinzler, 2004). The 
multi-hit model for tumor progression 
has particular relevance to tumor sup-
pressors, such as the BRCA genes. 
Women with BRCA mutations are 
highly susceptible to developing breast 
or ovarian cancers. BRCA protein is 
thought to suppress malignancies by 
promoting homologous recombina-
tion-dependent repair of DNA. Loss 
of BRCA function is thought to lead to 
malignancy as a consequence of sub-
sequent mutations caused by alterna-
tive repair pathways compensating for 
the primary repair defect. Two groups 
recently reported that secondary 
mutations at the BRCA2 locus, which 
restore the wild-type reading frame, in 
BRCA-deficient tumors may contribute 
to the development of resistance to 
chemotherapy (Edwards et al., 2008; 
Sakai et al., 2008)
Homologous recombination is 
required for repair of the frequent 
spontaneous lesions that arise during 
DNA replication. As a consequence, 
homologous recombination is also 
essential for cell viability and pro-
liferation. Given that a reduction in 
homologous recombination is disad-
vantageous to malignant progression, BRCA-deficient backgrounds select for 
mutations that promote the growth and 
survival of tumors. BRCA-mediated 
homologous recombination is also 
important for the response of cells to 
DNA-damaging agents that cause dou-
ble-strand breaks or replication forks 
to stall or collapse. Therefore, BRCA-
defective tumors can be hypersensi-
tive to cancer therapies that function 
by inducing recombinogenic lesions 
(Foulkes, 2006). Correspondingly, cells 
impaired in homologous recombination 
are hypersensitive to DNA-crosslinking 
drugs such as mitomycin C and cispla-
tin (Bhattacharyya et al., 2000); these 
cells are also hypersensitive to agents 
that inhibit poly(ADP-ribose) poly-
merase (PARP), because inhibition of 
PARP leads to collapsed DNA replica-
tion forks (Bryant et al., 2005; Farmer 
et al., 2005).
Secondary genetic or epigenetic 
changes that affect homologous 
recombination or cellular responses 
to DNA damage (such as apoptosis 
or cell-cycle checkpoints) can modify 
BRCA phenotypes (Martin et al., 2007 
and references therein). In the recent 
studies from the labs of Ashworth and 
Taniguchi, the genetic basis of acquired 
resistance to chemotherapy was inves-
tigated using the BRCA2 mutant human 
pancreatic cancer cell line CAPAN1 
(Edwards et al., 2008; Sakai et al., 
2008). CAPAN1 cells harbor two cop-Cell 13ies of a frameshift allele of BRCA2 that 
expresses an N-terminal protein frag-
ment. In both studies, drug-resistant 
cells were selected using a BRCA-spe-
cific agent (cisplatin or PARP inhibitor). 
This selection yields cells that acquire 
drug resistance from pseudo-reversion 
of BRCA2 via secondary frameshift 
mutations.
All the revertant BRCA2 alleles ex-
press between two and six BRC repeats, 
a nuclear localization sequence, and the 
TR2 domain, which is thought to regu-
late RAD51 loading onto single-stranded 
DNA (ssDNA). Interestingly, all revertants 
isolated using cisplatin selection (Sakai 
et al., 2008) contain the ssDNA-binding 
domain of BRCA2, whereas most rever-
tants isolated with PARP inhibitors (Ed-
wards et al., 2008) lack much or all this 
region. Previous observations suggested 
that the OB folds of BRCA2, which bind 
ssDNA, are required for its repair func-
tion (Saeki et al., 2006). However, the 
isolation of functional revertants lacking 
this domain indicates that either the OB 
folds are dispensable for DNA binding or 
that direct BRCA2-DNA interaction is not 
required for function.
Another intriguing observation con-
cerns the fraction of selected lines car-
rying BRCA2 revertants. In the case of 
the PARP inhibitor, all selected lines 
contain BRCA2 reversions. In con-
trast, only half (6/12) of the cisplatin-
selected lines are BRCA2 revertants; 2, March 21, 2008 ©2008 Elsevier Inc. 919
the mechanisms of cisplatin resistance 
for the remaining lines are unknown. 
Importantly, the amount of homolo-
gous recombination activity of the cis-
platin-resistant lines depends on the 
status of BRCA2. Taken together, these 
observations suggest that PARP inhibi-
tors exert a more specific selective 
pressure for the restoration of homolo-
gous recombination activity than does 
cisplatin.
Underscoring the physiological rele-
vance of genomic instability in BRCA2-
deficient cells, Edwards et al. detect 
short regions of sequence homology 
that flank the deletion sites in rever-
tant clones. This finding indicates that 
micro-homology-dependent end-join-
ing compensates for the deficiency in 
homologous recombination in CAPAN1 
cells. These secondary mutations are 
examples of the genetic instability 
caused by compensatory error-prone 
repair mechanisms.
Both papers also demonstrate that 
revertants of BRCA2 can occur clini-
cally following treatment of ovarian 
cancer with platinum-based therapy. 
Sakai et al. describe a recurrent ovar-
ian tumor containing an intragenic 
deletion that restores expression of 
functional BRCA2 via activation of 
cryptic splice sites. Furthermore, both 
groups describe BRCA2 revertants in 
cancers refractory to treatment from 
patients that carried frameshift BRCA2 
mutations similar to those present in 
CAPAN1 cells.
These studies demonstrate a com-
pelling model for the processes by 
which resistance can be acquired. It 
will be interesting to determine whether 
this mechanism of acquired resistance 
can be generalized to other BRCA gen-
otypes, as well as other cancer sus-
ceptibility genes. As the authors point 
out, the frameshift mutation of BRCA2 
may be particularly prone to reversion. 
The results also suggest a potential for 
choosing clinical treatments that are 
tailored to particular types of BRCA 
mutations.
The studies by Sakai and Edwards 
emphasize the opposing consequences 
of treating repair-deficient cancers 
with agents that induce DNA damage. 
Although treatment kills a large fraction 
of tumor cells, it also selects for cells 
with restored repair functions and resis-
tance to therapy. The development of 
revertant clones likely occurs via mecha-
nisms that compensate for essential 
house-keeping functions of the deficient 
repair pathways. Some of the mutagen-
esis may also be caused by the therapies 
themselves. This phenomenon, however, 
does not necessarily require mutagen-
esis or selection by a DNA-damaging 
therapy. For example, overexpression 
of RAD51 is frequently observed in 
BRCA mutant cells (Martin et al., 2007). 
Although RAD51 overexpression can 
partially compensate for the deficiency 
in homologous recombination, it might 
also promote a deregulated mutagenic 
version of homologous recombination 
that drives further malignant progres-
sion. It is interesting to consider that a 
cell with a profound repair defect, such 
as a BRCA−/−cell that is newly derived 
from a BRCA+/− heterozygote, might 
represent an intermediate cell type en 
route to a malignant cancer cell with par-
tially or completely restored capacity for 
repair and relatively less genome insta-
bility (Figure 1).
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figure 1. Model for Tumor Progression following Loss of a DnA Repair Pathway
Loss of a specific DNA repair pathway results in genetically unstable premalignant cells (red). Such cells 
can suffer from impaired proliferative capacity associated with the repair defect. Mutations accumulate 
in these cells, and those mutations conferring improved growth properties are selected (yellow). In some 
instances these derivatives may also acquire improved repair capacity (and reduced genetic instability) 
relative to their progenitors. Tumors are treated with drugs that act by generating lesions that challenge 
the defective repair pathway. This treatment imposes a strong selection for those mutations that further 
restore repair proficiency thereby generating drug-resistant clones (green). Treatment could also promote 
progression by directly forming mutagenic lesions.920 Cell 132, March 21, 2008 ©2008 Elsevier Inc.
